BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07700329 |
A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07242781 |
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants |
TERMINATED | PHASE1 |
| NCT06808984 |
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease |
RECRUITING | PHASE2 |
| NCT06782490 |
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity |
RECRUITING | PHASE2 |
| NCT06764485 |
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer |
RECRUITING | PHASE3 |
| NCT06425302 |
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06356129 |
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05519085 |
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) |
RECRUITING | PHASE3 |
| NCT04884035 |
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04855136 |
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma |
TERMINATED | PHASE1 |
